Bradycardia other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:


== Overview ==
== Overview ==
There are no other diagnostic studies associated with bradycardia.
Genetic mutations may potentially play a role in adult sinus node abnormalities and conduction difficulties, however most are caused by increasing vagal tone or inherited diseases. Despite the rarity of familial disorders of sinus node function and conduction abnormalities, a growing number of genetic mutations have been connected to a variety of abnormalities that may manifest as isolated conduction disease or SND or in conjunction with cardiomyopathy, congenital cardiac anomalies, noncardiac developmental disorders, skeletal muscular disorders, or tachyarrhythmias.


== Other diagnostic studies ==
Ion channel regulatory proteins, nuclear envelope proteins, membrane adaptor proteins, transcription factors, sarcoplasmic reticulum calcium handling proteins, gap junctions, cardiac hormones, and sarcomeric proteins are all encoded by the involved genes.
There are no other diagnostic studies associated with bradycardia.


== 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society<ref name="pmid30586772">{{cite journal|author=Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR|display-authors=etal|title=2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.|journal=Circulation|year=2019|volume=140|issue=8|pages=e382-e482|pmid=30586772|doi=10.1161/CIR.0000000000000628|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30586772}}</ref> ==
=== Recommendations for Genetic Testing in Documented or Suspected Bradycardia or Conduction Disorders ===
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen" |'''1.'''In patients in whom a conduction disorder-causative mutation has been identified, genetic counseling and mutation-specific genetic testing of first-degree relatives is recommended to identify similarly affected individuals. ''(Level of Evidence: C-EO)''
|}
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
| bgcolor="LemonChiffon" |'''1.'''In patients with inherited conduction disease, genetic counseling and targeted testing may be considered to facilitate cascade screening of relatives as part of the diagnostic evaluation.''(Level of Evidence: C-EO)''
|}
==References==
==References==



Revision as of 01:30, 28 December 2022

Bradycardia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bradycardia from other Conditions

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

Echocardiography

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bradycardia other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bradycardia other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bradycardia other diagnostic studies

CDC on Bradycardia other diagnostic studies

Bradycardia other diagnostic studies in the news

Blogs on Bradycardia other diagnostic studies

Directions to Hospitals Treating Bradycardia

Risk calculators and risk factors for Bradycardia other diagnostic studies

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Genetic mutations may potentially play a role in adult sinus node abnormalities and conduction difficulties, however most are caused by increasing vagal tone or inherited diseases. Despite the rarity of familial disorders of sinus node function and conduction abnormalities, a growing number of genetic mutations have been connected to a variety of abnormalities that may manifest as isolated conduction disease or SND or in conjunction with cardiomyopathy, congenital cardiac anomalies, noncardiac developmental disorders, skeletal muscular disorders, or tachyarrhythmias.

Ion channel regulatory proteins, nuclear envelope proteins, membrane adaptor proteins, transcription factors, sarcoplasmic reticulum calcium handling proteins, gap junctions, cardiac hormones, and sarcomeric proteins are all encoded by the involved genes.

2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[1]

Recommendations for Genetic Testing in Documented or Suspected Bradycardia or Conduction Disorders

Class I
1.In patients in whom a conduction disorder-causative mutation has been identified, genetic counseling and mutation-specific genetic testing of first-degree relatives is recommended to identify similarly affected individuals. (Level of Evidence: C-EO)
Class IIa
1.In patients with inherited conduction disease, genetic counseling and targeted testing may be considered to facilitate cascade screening of relatives as part of the diagnostic evaluation.(Level of Evidence: C-EO)

References

  1. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR; et al. (2019). "2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society". Circulation. 140 (8): e382–e482. doi:10.1161/CIR.0000000000000628. PMID 30586772.